Abstract
There are an important number of neurological diseases where not neurons but glia are the responsible cells for the degeneration of the nervous system. In the last years, determinant roles for oligodendrocytes (OLs) have been demonstrated not only in myelin generation and maintenance but also for metabolic support of neurons. Oligodendroglial defects lead to brain degeneration in several diseases, supporting the idea that not only endogenous regeneration but also administration of exogenous OL precursors will lead to overcome functional deficits. In this review, we discuss many diseases where OLs play a crucial role, and focus on the different sources and methods to obtain oligodendroglial cells that could be used in cell therapy for myelin-related and oligodendrocyte-deficient diseases.
Keywords: Amyotrophic lateral sclerosis, cell transplantation, leukodystrophies, multiple sclerosis, oligodendrocyte, stem cell therapy.
Current Stem Cell Research & Therapy
Title:Stem Cell-Derived Oligodendroglial Cells for Therapy in Neurological Diseases
Volume: 11 Issue: 7
Author(s): Juan A. García-León and Catherine M. Verfaillie
Affiliation:
Keywords: Amyotrophic lateral sclerosis, cell transplantation, leukodystrophies, multiple sclerosis, oligodendrocyte, stem cell therapy.
Abstract: There are an important number of neurological diseases where not neurons but glia are the responsible cells for the degeneration of the nervous system. In the last years, determinant roles for oligodendrocytes (OLs) have been demonstrated not only in myelin generation and maintenance but also for metabolic support of neurons. Oligodendroglial defects lead to brain degeneration in several diseases, supporting the idea that not only endogenous regeneration but also administration of exogenous OL precursors will lead to overcome functional deficits. In this review, we discuss many diseases where OLs play a crucial role, and focus on the different sources and methods to obtain oligodendroglial cells that could be used in cell therapy for myelin-related and oligodendrocyte-deficient diseases.
Export Options
About this article
Cite this article as:
García-León A. Juan and Verfaillie M. Catherine, Stem Cell-Derived Oligodendroglial Cells for Therapy in Neurological Diseases, Current Stem Cell Research & Therapy 2016; 11 (7) . https://dx.doi.org/10.2174/1574888X10666150902095312
DOI https://dx.doi.org/10.2174/1574888X10666150902095312 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued) Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Small Molecule Inhibitors of PKCθ as Potential Antiinflammatory Therapeutics
Current Topics in Medicinal Chemistry Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies
Current Medicinal Chemistry “The Tools of the Trade” – An Overview of the Pharmacology of the Endocannabinoid System
Current Pharmaceutical Design Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Nitric Oxide Induced Damage and Preventive Effect of Curcumin and Quercetin on Buffalo Brain Cystatin
Current Proteomics Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Use of Kv1.3 Blockers for Inflammatory Skin Conditions
Current Medicinal Chemistry Epigenetics in Multiple Sclerosis: Molecular Mechanisms and Dietary Intervention
Central Nervous System Agents in Medicinal Chemistry Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Nongenomic Actions of Thyroid Hormones: From Basic Research to Clinical Applications. An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)